Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced second-quarter 2026 net product revenue of approximately $13.5 million, a substantial increase from $2 million in the same period last year. The growth was primarily fueled by TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the company's flagship fibromyalgia treatment, which generated approximately $11 million in net sales during the quarter.
TONMYA's commercial performance showed robust momentum, with total prescriptions reaching 12,592, a 100% sequential increase. New patient prescriptions grew 36%, while refills saw a remarkable 207% rise. The drug now has coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. With a managed Medicare agreement set to take effect on Jan. 1, 2027, coverage is expected to expand to approximately 145 million lives.
Beyond commercial achievements, Tonix continues to advance its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study evaluating TNX-102 SL for major depressive disorder. Additionally, Tonix is preparing to initiate an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that these resources, combined with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments. TONMYA, approved as the first new treatment for fibromyalgia in over 15 years, is central to the company's CNS commercial infrastructure, which also includes acute migraine products Zembrace SymTouch and Tosymra. The company is exploring TONMYA's potential in Phase 2 trials for major depressive disorder and acute stress disorder. Other CNS pipeline assets include TNX-2900, Phase 2 ready for Prader-Willi syndrome, a rare disease.
In immunology, Tonix is advancing TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection. These product development candidates are investigational and have not been approved for any indication.
The announcement underscores Tonix's transition into a commercial-stage entity, with TONMYA's sales trajectory providing a strong foundation. The company's ability to secure broad coverage and grow prescription volumes is critical for sustained revenue growth. Additionally, the advancement of pipeline programs, particularly TNX-102 SL for major depressive disorder, could diversify its portfolio and address significant unmet medical needs. The company's cash position appears sufficient to support ongoing operations and development activities into 2027, offering a measure of stability in a volatile biotech market.
